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Background
Recurrent pericarditis is known to be a clinical feature
in numerous inflammatory and infectious diseases.
However, in the majority of cases, recurrent pericarditis
appears to be idiopathic. The optimal regimen for pre-
venting recurrence is not established; treatment modal-
ities include non-steroidal anti-inflammatory drugs
(NSAIDs), corticosteroids, colchicine and other immu-
nomodulatory agents as well as pericardiectomy. Long-
term prognosis of recurrent pericarditis is generally
good.
Case report
A previously healthy twelve years old boy was admitted
in March 2008 to our hospital with fever and thoracic
pain starting 3 days after a minor road traffic accident.
Pericardial (1.2 mm), left pleural (20 mm) and peritoneal
effusion were identified. Inflammatory markers were
markedly raised (PCR 271 mg/l and VSG 108 mm/h)
whilst full blood count and biochemistry were normal
(except Hb 10.4 g/l). Serology (viral and bacterial) and
immunology screening remained negative as was genetic
study testing for 12 genes for MEFV.
The diagnosis of idiopathic pericarditis was made and
treatment with oral corticosteroids (2 mg/kg) for 6
weeks resulted in a good clinical response; however
symptoms reoccurred repeatedly when steroids were
tapered even though colchicine was added. When
immunomodulatory therapy with Il-1R antagonist ana-
kinra (2 mg/kg/day) was initiated, steroids could be
withdrawn successfully. Then he suffered benign transi-
tory intracranial hypertension. Treatment with anakinra
was reduced after 10 months to 2m/kg alternating days
and successfully stopped in February 2011. He remains
clinically asymptomatic with normal inflammatory
markers.
Conclusions
1. Idiopathic recurrent pericarditis might be considered
an autoinflammatory syndrome.
2. Immunomodulation with Anakinra should be con-
sidered in the management of these patients who do not
maintain long term response using conventional
treatment.
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